Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

CXCL12 can both help and harm hair growth in alopecia areata.

Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Dupilumab significantly improved a 5-year-old girl's prurigo nodularis without side effects.

Finasteride boosts immune cells that suppress T-cells, possibly helping with immune disorders but may increase cancer risk.

Baricitinib stops hair loss and promotes regrowth in alopecia areata.

Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.

Dupilumab led to complete hair regrowth and improved skin condition in a young man with severe eczema and hair loss.

Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.

Mycophenolate mofetil can effectively treat autoimmune hepatitis when standard drugs fail.

Baricitinib is the most effective treatment for alopecia areata.

IL-36α helps in growing new hair follicles when healing wounds, potentially aiding in hair growth.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.

Understanding how Regulatory T Cells work could help create treatments for certain skin diseases and cancers.

Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.

SCD-153 shows promise as an effective topical treatment for alopecia areata.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

Myeloid-derived suppressor cells help control autoimmune cells and promote hair regrowth in alopecia areata.

17β-estradiol can reduce inflammation in the skin.

CD25+ CD4+ Tregs and certain plasma proteins are linked to hair loss.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.

Ruxolitinib can help regrow hair in severe alopecia areata.

Ruxolitinib effectively and safely regrows hair in alopecia patients.